FI101193B - Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i - Google Patents

Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i

Info

Publication number
FI101193B
FI101193B FI915826A FI915826A FI101193B FI 101193 B FI101193 B FI 101193B FI 915826 A FI915826 A FI 915826A FI 915826 A FI915826 A FI 915826A FI 101193 B FI101193 B FI 101193B
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical composition
physical form
physical
pharmaceutical
Prior art date
Application number
FI915826A
Other languages
English (en)
Swedish (sv)
Other versions
FI101193B1 (fi
FI915826A0 (fi
FI915826A (fi
Inventor
James Joseph Holohan
Ieuan John Edwards
Robert Joseph Timko
Randy John Bradway
Arlene Clements
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI101193(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of FI915826A0 publication Critical patent/FI915826A0/fi
Publication of FI915826A publication Critical patent/FI915826A/fi
Priority to FI972528A priority Critical patent/FI106021B/fi
Priority to FI980376A priority patent/FI980376A/fi
Application granted granted Critical
Publication of FI101193B1 publication Critical patent/FI101193B1/fi
Publication of FI101193B publication Critical patent/FI101193B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI915826A 1990-12-12 1991-12-11 Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i FI101193B (fi)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI972528A FI106021B (fi) 1990-12-12 1997-06-13 Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
FI980376A FI980376A (fi) 1990-12-12 1998-02-18 N-/4-/5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yylimetyyli/-3-metoksibentsoyyli/-2-metyylibentseenisulfonamidin fysikaalista muotoa sisältävä farmaseuttinen koostumus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (4)

Publication Number Publication Date
FI915826A0 FI915826A0 (fi) 1991-12-11
FI915826A FI915826A (fi) 1992-03-31
FI101193B1 FI101193B1 (fi) 1998-05-15
FI101193B true FI101193B (fi) 1998-05-15

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
FI915826A FI101193B (fi) 1990-12-12 1991-12-11 Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i

Country Status (30)

Country Link
US (6) US5319097A (fi)
EP (1) EP0490648B1 (fi)
JP (1) JP2585495B2 (fi)
KR (2) KR0183027B1 (fi)
CN (2) CN1043405C (fi)
AP (1) AP285A (fi)
AT (1) ATE131048T1 (fi)
AU (1) AU656157B2 (fi)
BE (1) BE1004229A5 (fi)
CA (2) CA2056066C (fi)
CZ (1) CZ283181B6 (fi)
DE (2) DE4140858A1 (fi)
DK (1) DK0490648T3 (fi)
ES (1) ES2079589T3 (fi)
FI (1) FI101193B (fi)
FR (1) FR2670488B1 (fi)
GB (2) GB2280606B (fi)
GR (1) GR3018318T3 (fi)
HK (2) HK81397A (fi)
HU (2) HU213211B (fi)
IE (1) IE75348B1 (fi)
IL (1) IL100091A (fi)
IT (1) IT1256282B (fi)
MX (1) MX9102473A (fi)
MY (1) MY106315A (fi)
NZ (1) NZ240939A (fi)
PH (1) PH30928A (fi)
RU (1) RU2106140C1 (fi)
SK (2) SK279813B6 (fi)
TW (1) TW276181B (fi)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (fi) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (fi) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
KR20020032611A (ko) * 1999-09-20 2002-05-03 스톤 스티븐 에프. 약물의 다형성 전환을 경감시키기 위한 공정
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CZ309209B6 (cs) * 2001-01-26 2022-05-25 Schering Corporation Farmaceutický prostředek
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
MXPA04000294A (es) * 2001-07-10 2004-05-04 Pharmacia & Upjhon Company Tiacin oxazolidinonas cristalinas.
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
EP1429756B1 (en) * 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
WO2009018280A2 (en) * 2007-07-30 2009-02-05 Auspex Pharamaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
JP7272655B2 (ja) 2017-01-30 2023-05-12 ウェスタン ニュー イングランド ユニバーシティ チオールイソメラーゼ阻害剤およびその使用
WO2019130334A1 (en) 2017-12-28 2019-07-04 Council Of Scientific & Industrial Research Process for the preparation of zafirlukast and analogs thereof
CA3219671A1 (en) 2021-05-19 2022-11-24 Thomas Christian Lines Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
SK279813B6 (sk) 1999-04-13
US5319097A (en) 1994-06-07
US5993859A (en) 1999-11-30
EP0490648B1 (en) 1995-12-06
DE69115229T2 (de) 1996-05-09
FR2670488B1 (fr) 1994-01-28
KR970005014A (ko) 1997-01-29
PH30928A (en) 1997-12-23
CN1043405C (zh) 1999-05-19
AP285A (en) 1993-09-23
GB9418154D0 (en) 1994-10-26
SK279814B6 (sk) 1999-04-13
HU213211B (en) 1997-03-28
IE75348B1 (en) 1997-08-27
MX9102473A (es) 1992-06-01
ITMI913324A1 (it) 1993-06-11
EP0490648A1 (en) 1992-06-17
GB9126354D0 (en) 1992-02-12
US5612367A (en) 1997-03-18
GB2280606A (en) 1995-02-08
US5482963A (en) 1996-01-09
CA2319308A1 (en) 1992-06-13
KR0183027B1 (ko) 1999-05-01
FI101193B1 (fi) 1998-05-15
HU913865D0 (en) 1992-02-28
GB2251791B (en) 1995-05-17
CA2319308C (en) 2001-08-21
CN1105705C (zh) 2003-04-16
CS375691A3 (en) 1992-06-17
HU211126A9 (en) 1995-10-30
ES2079589T3 (es) 1996-01-16
GB2280606B (en) 1995-05-17
CN1062291A (zh) 1992-07-01
US6143775A (en) 2000-11-07
GR3018318T3 (en) 1996-03-31
AU8899491A (en) 1992-06-18
RU2106140C1 (ru) 1998-03-10
GB2251791A (en) 1992-07-22
JPH04266824A (ja) 1992-09-22
IL100091A (en) 1998-08-16
TW276181B (fi) 1996-05-21
NZ240939A (en) 1994-05-26
DK0490648T3 (da) 1996-05-06
JP2585495B2 (ja) 1997-02-26
CZ283181B6 (cs) 1998-01-14
CN1243827A (zh) 2000-02-09
HK81397A (en) 1997-06-27
ITMI913324A0 (it) 1991-12-11
KR920011493A (ko) 1992-07-24
IL100091A0 (en) 1992-08-18
AU656157B2 (en) 1995-01-27
CA2056066A1 (en) 1992-06-13
US5504216A (en) 1996-04-02
HUT61281A (en) 1992-12-28
MY106315A (en) 1995-04-29
CA2056066C (en) 2002-04-02
AP9100340A0 (en) 1992-01-31
FR2670488A1 (fr) 1992-06-19
IT1256282B (it) 1995-11-29
HK81597A (en) 1997-06-27
FI915826A0 (fi) 1991-12-11
KR100207802B1 (ko) 1999-07-15
BE1004229A5 (fr) 1992-10-13
DE4140858A1 (de) 1992-06-17
IE914310A1 (en) 1992-06-17
DE69115229D1 (de) 1996-01-18
ATE131048T1 (de) 1995-12-15
FI915826A (fi) 1992-03-31

Similar Documents

Publication Publication Date Title
FI101193B (fi) Menetelmä N-£4-£5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3 -yyli-metyyli|-3-metoksibentsoyyli|-2-metyylibentseenisulfonamidin fys ikaalista muotoa sisältävän farmaseuttisen koostumuksen valmistamiseks i
FI905941A (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten 2-asyyliaminotiatsolijohdannaisten valmistamiseksi
FI913248A0 (fi) Kontrollerat frigoerande fast farmaceutisk doseringsform.
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
FI893520A (fi) Menetelmä intravenoosisen farmaseuttisen koostumuksen valmistamiseksi
SE8801813D0 (sv) Pharmaceutical composition
FI930723A0 (fi) Menetelmä terapeuttisesti aktiivisten tiatsolidiinijohdannaisten valmistamiseksi
FI93444B (fi) Menetelmä terapeuttisesti aktiivisten dihydropyridiinijohdannaisten valmistamiseksi
FI93106C (fi) Menetelmä lääkeaineina käyttökelpoisten 2-iminobentsotiatsoliinijohdannaisten valmistamiseksi
NO175976C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
FI92065C (fi) Menetelmä farmaseuttisten piperidiinijohdannaisten valmistamiseksi
FI895983A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 2-bentsotiatsoliinijohdannaisten valmistamiseksi
ITMI910456A0 (it) Composizione farmaceutica per il trattamento della cataratta
PT87024A (pt) Process for the preparation of propiolophenone derivatives and of pharmaceutical compositions containing the same
FI903077A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia R(-)-3-kinuklidinolijohdannaisia
PT88681A (pt) A process for the preparation of pharmaceutical compositions containing piperidinoalkanol derivatives
FI831619A0 (fi) 2(1h)-pyridinonderivat, deras framstaellning och dessa innehaollande farmaceutiska produkter
FI911701A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
PT87679A (pt) A process for the preparation of 2-methoxymethyl-penem derivatives and of pharmaceutical compositions containing the same
FI915785A (fi) Menetelmä 3-asemassa substituoitujen tiofeenien valmistamiseksi
IT1223132B (it) Composizione farmaceutica per somministrazione nasale
PT86933A (pt) Process for the preparation pf optically active oxo-isoindolinyul derivatives and of pharmaceutical compositions containing the same
PT87572A (pt) Process for the preparation of pyrazines amino-methyl-phenolicsand of pharmaceutical compounds containing them
NO903397L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av protocatechualdehyd.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ZENECA LIMITED

MA Patent expired